Asthma Clinical Trials

Find Asthma Clinical Trials Near You

Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma

Status: Recruiting
Location: See location...
Intervention Type: Device, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study evaluates the diagnostic performance, usability, and clinical utility of the Medentum Diagnostik platform, a multisensor device with integrated software and artificial intelligence, in pediatric patients with asthma and ENT conditions. Participants will be assigned to either home-based use of the Diagnostik platform with telehealth-supported clinician evaluation or standard in-person care. The primary objective is to assess agreement between AI-generated diagnoses and clinician diagnoses obtained during study encounters, including telehealth evaluations in the Diagnostik arm and in-person evaluations in the standard-of-care arm. Secondary objectives include evaluating agreement between AI-generated diagnoses and independent research team diagnoses, as well as assessing usability, patient and caregiver satisfaction, healthcare utilization, and clinical outcomes such as asthma control and symptom resolution. This study will also evaluate differences in healthcare utilization, including in-person visits, emergency care use, and time to diagnosis and treatment, between study groups.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 17
Healthy Volunteers: t
View:

• Age: Patients between the ages of 4 and 17 years (asthma) and 3-17 years (ENT)

• Diagnosis:

• o Asthma patients: Diagnosed with mild-to-moderate and severe persistent asthma according to Global Initiative for Asthma (GINA) guidelines, with a history of symptoms or exacerbations requiring medical intervention (prior prednisone course and/or albuterol for \>24 hours in context of acute wheezing episode) in the past 12 months. ENT patients: Diagnosed with common ENT conditions such as acute otitis media (AOM) or strep pharyngitis in the prior year. Diagnosis must be based on established clinical guidelines.

• Technology access: Must have access to a smartphone, tablet, or other device capable of running the Medentum Diagnostik platform app and access to Wifi or cellular service.

• Care access: Must be receiving routine care from University of Arizona or associated clinics in Arizona and have active health insurance

• Consent: Must have parental or guardian consent for participation, as well as child assent when appropriate.(all children ≥7 yrs)

Locations
United States
Arizona
El Rio Health System
RECRUITING
Tuscon
Contact Information
Primary
Starla Kiser, Medical Degree
starla@medentum.com
276-212-1863
Time Frame
Start Date: 2025-10-01
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 84
Treatments
Experimental: Moderate-to-severe pediatric asthma patients with home-based use of Diagnostik platform
Intervention Group with in-office standard of care for routine well visits, urgent care/ED visits as needed plus using the Medentum Diagnostik platform (multisensor device, + app+ AI platform) for telehealth management of asthma
Placebo_comparator: Moderate-to-severe pediatric asthma patients using standard-of-care asthma management
Control Group receiving in-office standard of care for routine well visits, and urgent care/ED visits as needed. No Diagnostik platform use.
Placebo_comparator: Pediatric ENT patients with standard-of-care ENT management
Control Group receiving in-office standard of care for routine well visits, and routine care, urgent care/ED visits as needed.
Experimental: Pediatric ENT patients with home-based use of Diagnostik platform
Intervention Group with in-office standard of care for routine well visits, urgent care/ED visits as needed plus using the Medentum Diagnostik platform for telehealth for ENT conditions
Related Therapeutic Areas
Sponsors
Leads: Medentum Innovations
Collaborators: University of Arizona, National Institutes of Health (NIH), El Rio Community Health Center

This content was sourced from clinicaltrials.gov